Loading...
•
Sep 30, 2022
Bioxcel Therapeutics Q3 2022 Earnings Report
BioXcel Therapeutics reported financial results for Q3 2022 and provided an update on key strategic initiatives.
Key Takeaways
BioXcel Therapeutics reported net revenue of $137,000 for the third quarter of 2022. The company's net loss was $41.8 million, and cash and cash equivalents totaled approximately $232.3 million as of September 30, 2022.
IGALMI well-positioned for growth in 2023 based on increasing market access, efficient targeting, favorable market drivers, and sales force expansion in all major U.S. geographies
Top-line pivotal data for TRANQUILITY II trial investigating BXCL501 for Alzheimer’s-related agitation expected in 1H 2023
Top-line pivotal data for SERENITY III trial investigating at-home use of BXCL501 for acute treatment of bipolar and schizophrenia-related agitation expected in 1H 2023
Completed multiple, seven-day daily dosing regimen cohorts in ongoing Phase 1 dose-selection trial in healthy volunteers to assess Major Depressive Disorder (MDD) program for at-home use; top-line results expected in 1H 2023
Bioxcel Therapeutics
Bioxcel Therapeutics
Bioxcel Therapeutics Revenue by Segment
Revenue by Segment
IGALMI Revenue
CapyFin.com Forward Guidance
BioXcel Therapeutics is anticipating pivotal trial data readouts investigating BXCL501 for the treatment of Alzheimer’s-related agitation, and bipolar and schizophrenia-related agitation in an at-home setting.